News

Allon trial studies pharmacokinetics of AL-108 & AL-208

VANCOUVER, January 10, 2008— Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced today that it had commenced dosing in a Phase I clinical trial to evaluate the pharmacokinetics of AL-108 (intranasal administration) or AL-208 (intravenous administration) in the blood and ... Continue reading →

Allon Therapeutics confirms milestones for 2008

VANCOUVER, January 8, 2008— Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, confirmed today that its 2008 milestones include results from three Phase II human clinical trials that will indicate whether the Company’s drugs AL-108 and AL-208 have an effect on three of the most u... Continue reading →

Allon Therapeutics completes dosing in Phase II clinical trial in Alzheimer’s program

VANCOUVER, December 18, 2007 — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced today that it has completed patient dosing for its Phase II clinical trial evaluating the safety and efficacy of the Company’s proprietary drug candidate AL-108 in patients with amnestic m... Continue reading →

Allon Therapeutics releases third quarter operating results

VANCOUVER, November 12, 2007 — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, today reported its third quarter operating results. Highlights of this quarter include the continued advancement of the Company’s three Phase II human efficacy programs, with patient screening havin... Continue reading →

Allon to participate at two major conferences

VANCOUVER, October 24, 2007 — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced today that it will be participating this week at the prestigious Windhover Therapeutics Area Partnership conference, Allon had been selected by an expert panel as one of the “Top 10” not ye... Continue reading →

← Older posts Newer posts →